Science Ethics News Today

Part of. Your story you are trying always to understand this your culture. Or another visitor or not and yet you want to become a citizen. Migrants your platform for reliable information. This is d w news africa coming up in the next 15 minutes the new. Rules by the International Association of Athletics Federations will hear from kenyas limpid brands made in this. Chief is the new regulation could be a career into. Athletes as it has been slow in syria and its an initiative tactic Domestic Viol...

This is news africa coming up in the next 15 minutes the new. Rules by the International Association of Athletics Federations well hear from kenya. In this. New regulation could be a career into. Athletes visit a Husband School in syria and its an initiative Domestic Violence by teaching men not to abuse their wives. Im christine one the welcome to news africa im glad. Its a decision that could reshape the world. This month south africa rana cost us a man you lost her case at the Court Of Arbitr...

Behavior-based interventions could boost conservation efforts, but raise their own set of tricky ethical issues.

From Aristotle to Darwin, inaccurate and biased narratives in science not only reproduce these biases in future generations but also perpetuate the discrimination they are used to justify.

At least not with the current level of scientific advancement.

How can people strengthen their connections to natural world? That was the question addressed during this year’s December Dialogues, an event hosted by the Dialogue on Science Ethics, & Religion (DoSER) program of the American Association for the Advancement of Science.

Bilim-Emperyalizm Evlenirse-2

台股新聞 facebook comment 逸達 (6576-TW) 今 (5) 日公告，開發中的新成分新藥 FP-025，用於治療新冠病毒引起的急性呼吸窘迫症候群 (ARDS) 二 / 三期臨床試驗，首批試驗者數據經獨立資料監視委員會 (IDMC) 審查通過，預計今年第 4 季進行期中分析。 逸達表示，此臨床試驗採隨機、雙盲、安慰劑對照的多中心二 / 三期臨床試驗，用以評估 COVID-19 重症 / ARDS 病患服用 FP-025 的療效及安全性�...

逸達表示，將持續加開試驗點加速試驗，力拚2021年第四季取得二期臨床試驗數據。 獨立資料監視委員會（Independent Data Monitoring Committee IDMC）由獨立的臨床醫師、學者等所組成，在臨床試驗中將檢視受試病人的安全或藥物的有效性，並提出重要建議，以確保臨床試驗在符合科學倫理的最高標準下進行，並降低受試病人的風險。 此隨機、雙盲、安慰劑對照之多中心二/三期臨床試...

財訊新聞 　 【財訊快報／記者何美如報導】逸達生技(6576)新成分新藥FP-025用於治療COVID-19引起的急性呼吸窘迫症候群（Acute Respiratory Distress Syndrome, ARDS）二/三期臨床試驗，今日宣布首批受試者的安全性數據已通過獨立資料監視委員會（Independent Data Monitoring Committee, IDMC）審核，獲得正面意見，將持續加開試驗點加速試驗，預計2021年第四季取得二期臨床試驗數據。 急性呼吸�...